SCHEMBL2118995

SCHEMBL2118995

C=CCCCCCC[CH]C

nearest known ligand 0.60

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.60
ALDH1A1 P00352 4/20 0.50
MAPT P10636 2/20 0.44
ABCC4 O15439 1/20 0.44
LMNA P02545 3/20 0.43
TRPA1 O75762 2/20 0.41
LPAR3 Q9UBY5 2/20 0.38
LPAR2 Q9HBW0 1/20 0.38
USP2 O75604 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
HPGD P15428 1/20 0.34
CYP3A4 P08684 1/20 0.33
RECQL P46063 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10705131 1.00 TSHR (0.60) TSHRALDH1A1MAPTABCC4LMNA
SCHEMBL1454941 1.00 TSHR (0.60) TSHRALDH1A1MAPTABCC4LMNA
SCHEMBL3631631 1.00 TSHR (0.60) TSHRALDH1A1MAPTABCC4LMNA
SCHEMBL8478174 1.00 TSHR (0.60) TSHRALDH1A1MAPTABCC4LMNA
SCHEMBL2024971 1.00 TSHR (0.60) TSHRALDH1A1MAPTABCC4LMNA
SCHEMBL2023325 1.00 TSHR (0.60) TSHRALDH1A1MAPTABCC4LMNA
SCHEMBL1454349 1.00 TSHR (0.60) TSHRALDH1A1MAPTABCC4LMNA
SCHEMBL2119942 1.00
SCHEMBL1047033 0.97
SCHEMBL1453928 0.90

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021005997-A1 COMPOSITION CONTAINING COLORING AGENT 住友化学株式会社 2021-01-14 WO disclosed
WO-2020226099-A1 COLORED CURABLE RESIN COMPOSITION 住友化学株式会社 2020-11-12 WO disclosed
EP-2444401-B1 NOVEL IMIDAZOPYRIDINE COMPOUND ONO PHARMACEUTICAL CO (JP) 2014-09-03 EP disclosed
US-8569504-B2 Imidazopyridine compound ONO PHARMACEUTICAL CO., LTD. (JP) 2013-10-29 US disclosed
EP-2444401-A1 NOVEL IMIDAZOPYRIDINE COMPOUND ONO Pharmaceutical Co., Ltd. (JP) 2012-04-25 EP disclosed
US-20120094944-A1 NOVEL IMIDAZOPYRIDINE COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2012-04-19 US disclosed
EP-1733724-A1 AMINO ALCOHOL COMPOUND Sankyo Company, Limited (JP) 2006-12-20 EP disclosed
EP-1061076-B1 N-ACYL CYCLIC AMINE DERIVATIVES BANYU PHARMA CO LTD (JP) 2004-12-08 EP disclosed
EP-1061076-A1 N-ACYL CYCLIC AMINE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2000-12-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094944-A1 NOVEL IMIDAZOPYRIDINE COMPOUND CMA1, ACE, ALPI TSHR 4076/4885ALDH1A1 539/4885MAPT 4013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.